What Lisitens (Lercanidipin) Treats: Main Uses and Benefits

The primary therapeutic role of Lisitens is the management of chronic high blood pressure, known medically as essential hypertension. The medication's main indication is the treatment of mild to moderate essential hypertension in adults. The medication addresses the fundamental symptomatic pattern of elevated systemic vascular pressure, providing support that contributes to stability.

Lisitens is commonly used to help with conditions characterized by the sustained elevation of blood pressure. In clinical settings, it is relevant for managing various disease severities, including Mild Hypertension, Moderate Hypertension, and Resistant Hypertension (when used as an addition to other treatments). The main benefit provided is that the drug supports the lowering of elevated vascular pressure. By consistently managing blood pressure, it is relevant in managing conditions associated with long-term cardiovascular risk and assists with maintaining functional stability in vital organs like the heart and kidneys.

“It provides supportive relief that helps ease the overall symptom burden associated with constant pressure on the circulatory system.”

Lisitens (Lercanidipine) is officially approved for use in adults for the treatment of mild to moderate essential hypertension. The medicine is not recommended for children and adolescents under the age of 18, as clinical experience is not established in this population.

Use is strictly contraindicated in several groups due to absolute non-eligibility rules defined in regulatory documents:

Lercanidipine is also contraindicated in patients with known hypersensitivity to the medicine or any dihydropyridine. The regulatory label specifies that special care or caution is required when treating the elderly and patients with non-severe hepatic or renal dysfunction. These conditions introduce limitations requiring conditional use.

Interactions with other medicines and products

The interaction profile for Lisitens (Lercanidipin) is largely defined by its metabolism through the CYP3A4 enzyme system, as documented in regulatory guidelines. The official label specifies combinations that are strictly prohibited (contraindicated) and those that require cautious use due to altered drug exposure.

Formally Contraindicated Combinations

Interactions Requiring Caution

Co-administration with CYP3A4 inducers (e.g., Phenytoin, Rifampicin) may decrease Lercanidipin plasma levels, potentially resulting in lower systemic exposure. The combination with Simvastatin requires timing separation (Lercanidipin in the morning, Simvastatin in the evening) to manage the increased Simvastatin exposure. Consumption of alcohol must be avoided as it can potentiate the hypotensive effect. Additionally, the medication is contraindicated in patients with severe hepatic or severe renal impairment ( GFR < 30 ml/min) due to the heightened risk of drug accumulation.

Targeted Blockade of Vascular Calcium Channels

Lercanidipine functions as a selective antagonist of the L-type voltage-gated calcium channels ( Cav1.2), which are primarily localized on the vascular smooth muscle cells (VSMCs) of peripheral arterioles. The interaction is voltage-dependent, meaning the molecule preferentially blocks channels in a depolarized state, characteristic of vascular tone. By restricting the influx of extracellular calcium ions ( Ca^2+) into the VSMCs, the fundamental signal required for muscle contraction is interrupted.

Inhibition of Smooth Muscle Contraction

The restricted entry of Ca^2+ directly inhibits the activation of the intracellular enzyme Myosin Light Chain Kinase ( MLCK). Since MLCK activation is necessary for the interaction of muscle filaments, its suppression leads to the relaxation of the arterial smooth muscle tissue, resulting in arteriolar vasodilation (widening of the blood vessels).

Sustained Reduction of Peripheral Resistance

This localized vasodilation acts systemically by reducing the Total Peripheral Resistance (TPR)—the friction the blood encounters during circulation. Lercanidipine's high affinity for the vessel wall (lipophilicity) supports a sustained blockade, supporting the maintenance of this reduction in TPR, which is the primary physiological consequence of this mechanism.

Lisitens is administered by the oral route as a film-coated tablet and is used for long-term management. Standard instructions for use detail the required dose, frequency, and specific conditions for proper administration.

Official Dosing and Frequency

Administration Conditions

For proper absorption and efficacy, the administration of Lisitens is governed by specific rules concerning food and beverages:

• Timing: The dose must be taken at least 15 minutes before breakfast or any other meal. Taking the medication with food significantly increases its bioavailability.
• Intake: The tablets should be swallowed whole with a sufficient amount of water.
• Forbidden Intake: Grapefruit or grapefruit juice must not be consumed, as it can increase the drug's systemic availability and its intended effect. Alcohol should also be avoided as it may potentiate the effect of vasodilating drugs.

Use in Specific Populations

Prescribing information includes specific high-level guidance for certain patient groups:

• Older Adults: No initial dose adjustment is typically required, but treatment should be commenced with special care.
• Renal/Hepatic Impairment: Special care is needed for patients with mild to moderate dysfunction. Increasing the daily dose to 20 mg must be approached with caution. The drug is not recommended for use in patients with severe impairment.
• Pediatric Patients: Use in children and adolescents under 18 years of age is not currently recommended due to a lack of clinical data.

Research evidence / Overview of studies for Lisitens (Lercanidipine)

High Blood Pressure (Hypertension)

Research exploring Lisitens for high blood pressure primarily involves randomized controlled trials, which are studies often used for comparing a drug's outcomes to either a dummy pill (placebo) or another active medication. Research has explored Lisitens' effect, and findings indicate that its use is associated with reduced systolic blood pressure (the top number) and diastolic blood pressure (the bottom number).

When compared in trials to some other medications in the same class (called calcium channel blockers), studies examined whether there were differences in blood pressure change. While research generally suggests an association between Lisitens and blood pressure management, a key area of uncertainty is the long-term impact on major heart-related events, such as heart attack and stroke. There is limited direct, long-term evidence specifically from large-scale studies to show an effect of Lisitens on these major outcomes.

Special Populations in Hypertension

Research has also looked at how Lisitens is associated with blood pressure management in specific groups, including elderly patients and those with other conditions like diabetes or kidney impairment.

For elderly patients, studies have compared Lisitens with other blood pressure medications and indicated it was associated with similar changes in blood pressure. For patients with kidney impairment, research suggests an association between Lisitens use and a change in a marker called microalbuminuria, which is used to monitor kidney health. Some studies compared this effect to that of other classes of drugs, such as ramipril, finding comparable changes in microalbuminuria.

Limitations exist because many of these studies are shorter-term or do not directly focus on preventing major, long-term health problems over many years. This means that while the effect on blood pressure in these groups is generally indicated, the long-term health outcomes for high-risk patients remain an area where more comprehensive research would be valuable.

Official Storage and Disposal Requirements

Regulatory agencies specify strict conditions for the storage and disposal of Lercanidipine to maintain drug stability and ensure safety. These requirements are defined in official labeling, such as the Summary of Product Characteristics (SmPC) and Patient Information Leaflets.

Storage Constraints

Disposal Rules

Any unused or expired Lercanidipine must be disposed of in accordance with local requirements. This mandate prohibits throwing the medicine away via wastewater or household waste to protect the environment. Patients are instructed to consult their pharmacist for guidance on appropriate collection programs.